Covaxin Found To Have 77.8% Efficacy Rate Against Symptomatic Covid-19 Patients In Lancet Study

Bharat Biotech's Covaxin Is 77.8% Effective Against Symptomatic Covid-19 Patients: Lancet


  • According to the Lancet, Bharat Biotech’s Covaxin had a 77.8 percent effectiveness rate in treating symptomatic Covid-19 patients.
  • Covaxin ‘induces a significant antibody response’ two weeks after two doses are given.

Covaxin, a Covid-19 vaccination developed by the Bharat Biotech International Ltd. and government’s medical research agency, was demonstrated to be efficacious against symptomatic Covid-19 in a long-awaited study published in The Lancet.

Covaxin, which use conventional, inactivated-virus technology, “induces a significant antibody response” two weeks after two doses, according to The Lancet. According to the medical publication, no serious vaccine-related fatalities or adverse events were observed during a randomised trial comprising 24,419 participants aged 18-97 years in India between November 2020 and May 2021.

The initial report was funded by officials from Bharat Biotech and the Indian Council of Medical Research (ICMR) and co-authored by officials from both the organisations, is in line with the company’s previous efficacy and safety announcements and may help put an end to the controversy surrounding the shot’s early approval in India in January.

Also Read: Covaxin Gets SEC Emergency Approval For Children Aged Two To Eighteen

At the time, the vaccine had not yet cleared final-stage testing, causing considerable hesitancy in the early weeks of the vaccination campaign. Since then, more than 100 million doses of Covaxin have been administered throughout India, and the World Health Organization has added the vaccine to its list of Covid vaccines approved for emergency use.

However, during its analysis, the WHO’s independent technical body studying the vaccine repeatedly requested additional information from the company, delaying its inclusion on the body’s pre-qualified causing frustration to Prime Minister Narendra Modi’s government, which had advocated the locally developed shot.

Bharat Biotech Chairman Krishna Ella had previously slammed people who questioned Covaxin, and last week told in a conference that WHO clearance took so long because of criticism of the vaccine, which harmed company reputation. According to The Lancet, more study will be needed to determine the vaccine’s long-term safety and efficiency, as well as its capability to guard against severe sickness, hospitalisation, and mortality, as well as its ability to fight against delta and other variants of concern.

Subscribe to get the best stories into your inbox!
Swastika Dubey
Swastika Dubey is a content writer who has a keen interest in politics, fashion, and lifestyle. She is a post-graduate in Economics and loves to listen to classic old Hindi songs and travel to new places in her leisure time. Her writing is well researched, covering important aspects and core of the topic covering crucial points.
Leave a Reply

Your email address will not be published. Required fields are marked *

Editor's choice
Jet Airways To Take Flight Again From Early 2022, Company Starts Hiring Process
Bombay HC Dismisses Kangana Ranaut's Plea Seeking Quashing Of Defamation Case By Javed Akhtar
Financial Tasks You Must Complete Before 30 September 2021
Paytm Money Launches “WealthBaskest” An Investment Advisory Marketplace
Subscribe To Our Newsletter

Join our mailing list to receive the latest news and updates from our team.